ARN News

Originally published on PRNewsWire.com WASHINGTON, Oct. 8, 2019 /PRNewswire/ — Trio Health, a leading provider of real-time data on real-world patients, today announced the creation of the

Originally published in Rheumatology Network The price of a medication can be a significant factor in poor adherence to treatment, and few other specialties have

by Colin Edgerton, MD Articularis Rheumatology Network is announcing a name change to American Rheumatology Network (ARN). This is a coming of age moment for

In episode three, Dr. Hausmann and his guests, Dr. Colin Edgerton, chair of the ACR’s Committee on Rheumatologic Care and Dr. Angus Worthing, chair of

Originally published in Rheumatology Network Better treatment outcomes have been documented in studies when physicians and pharmacists work together. During last year’s American College of

Originally published in Rheumatology Network Affordability is a leading cause of drug abandonment among rheumatology patients. Out-of-pocket costs can be substantial. For example, rheumatoid arthritis

ARN’s CEO Ray Waldrup is looking forward to exhibiting at the NORM 2019 conference in a couple of days! Stop by Booth 3 for more

Originally published in Biosimilar Development by Anna Rose Welch, Editor It never ceases to excite me when I hear that some organization, hospital, or clinic

Originally published in the The Center For Biosimilars Web Site It’s no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in

Originally published in Biosimilar Development by Anna Rose Welch, Editor Generally speaking, when it comes to fixing or advancing the U.S. healthcare system, it’s easier

TSI Healthcare, the national leader in the sales and support of customized rheumatology specific solutions, hosted its inaugural Rheumatology User Group Meeting August 2-3, 2019

Originally published in The Center for Biosimilars Biosimilars have struggled to gain ground in the United States, with few products launched, relatively low uptake of

By Colin C. Edgerton, M.D. Biosimilar Adoption Falters Rheumatologists hoped that biosimilars would reduce the costs of treating diseases such as rheumatoid arthritis (RA), and

The field of rheumatology is experiencing a workforce shortage that is expected to worsen in years to come, and many patients living with rheumatic disease

Originally published in PR Web TSI Healthcare, a national leader in the sales and support for NextGen Practice Management (PM) and Electronic Health Records (EHR)